Abstract

Patients with metastatic seminoma typically present with stage II disease. Metastatic seminoma is highly curable because of the efficacy of radiotherapy and chemotherapy, although controversies remain over the best treatment strategy for stages IIA and IIB. According to available guidelines, radiotherapy is preferred in stage IIA seminoma, whereas cisplatin-based chemotherapy should be the first choice in stage IIB seminoma. Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trialDespite the fact that the primary endpoint was not met, we observed favourable 3-year progression-free survival with single-dose carboplatin area under the curve 7 and involved-node radiotherapy, with minimal toxic effects. Our findings might warrant discussion with patients about the SAKK 01/10 regimen as an alternative to standard-of-care treatment, but more research on this strategy is needed. Full-Text PDF

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call